15 Sep Stratatech receives NIA grant
Madison, Wis. – Stratatech Corp. has received a $154,000 Phase I STTR Grant from the National Institute on Aging, a division of the National Institutes of Health, for work in development of cell-based gene therapy products for the use in the treatment of chronic skin ulcer conditions affecting the elderly, such as venous stasis and pressure ulcers.
It is estimated that in the United States alone, more than 1,000,000 people annually suffer from either chronic venous stasis or pressure ulcers, with pain, infection and even amputation as complications that could damage a patient’s quality of life.
Stratatech is working to develop human skin substitutes which will neutralize the proteolytic environment in chronic wounds, thereby hastening the healing process. To date, no biological treatment options specifically targeting the proteolytic nature of chronic wounds have been developed and marketed.
Stratatech, which currently has 25 employees, was established in 2000 and currently operates within the MGE Innovation Center at the University Research Park in Madison. Stratatech’s products are based on a patented source of pathogen-free human skin cells that was identified at the University of Wisconsin-Madison.
Click here for previous WTN coverage of Stratatech.